Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (141-150 of 302) with videos related to

Pageof 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphomaAbdulwahab J Al-Tourah, Karamjit K Gill, Mukesh Chhanabhai, et al.
British Journal of Haematology|October 15, 2016
Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab eraRobert Kridel, David Telio, Diego Villa, et al.
British Journal of Haematology|May 14, 2022
Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British ColumbiaKai Zhu, Andrew Jamroz, Steven Huang, et al.
Blood|July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Ajay K Gopal, Scott E Smith, et al.
International Journal of Cancer|August 28, 2007
Organochlorines and risk of non-Hodgkin lymphomaJohn J Spinelli, Carmen H Ng, Jean-Philippe Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British ColumbiaLaurie H Sehn, Jane Donaldson, Mukesh Chhanabhai, et al.
Blood|December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphomaAjay K Gopal, Robert Chen, Scott E Smith, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 24, 2020
Tattoos and Hematologic Malignancies in British Columbia, CanadaFreda M Warner, Maryam Darvishian, Terry Boyle, et al.
Blood|May 1, 2008
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOPRaquel Malumbres, Jun Chen, Rob Tibshirani, et al.
Genes, Chromosomes & Cancer|March 23, 2004
Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21Laura-Jane Henderson, Ichiro Okamoto, Valia S Lestou, et al.
Pageof 31

Showing results (141-150 of 302) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2008
Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphomaAbdulwahab J Al-Tourah, Karamjit K Gill, Mukesh Chhanabhai, et al.
British Journal of Haematology|October 15, 2016
Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab eraRobert Kridel, David Telio, Diego Villa, et al.
British Journal of Haematology|May 14, 2022
Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British ColumbiaKai Zhu, Andrew Jamroz, Steven Huang, et al.
Blood|July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Ajay K Gopal, Scott E Smith, et al.
International Journal of Cancer|August 28, 2007
Organochlorines and risk of non-Hodgkin lymphomaJohn J Spinelli, Carmen H Ng, Jean-Philippe Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British ColumbiaLaurie H Sehn, Jane Donaldson, Mukesh Chhanabhai, et al.
Blood|December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphomaAjay K Gopal, Robert Chen, Scott E Smith, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 24, 2020
Tattoos and Hematologic Malignancies in British Columbia, CanadaFreda M Warner, Maryam Darvishian, Terry Boyle, et al.
Blood|May 1, 2008
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOPRaquel Malumbres, Jun Chen, Rob Tibshirani, et al.
Genes, Chromosomes & Cancer|March 23, 2004
Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21Laura-Jane Henderson, Ichiro Okamoto, Valia S Lestou, et al.
Pageof 31